Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 3/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.33 |
| ▸ | FEN1 | P39748 | 6/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | TYK2 | P29597 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | JAK3 | P52333 | 2/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30726167 | 0.94 | JAK2 (0.33) | P2RX3P2RX2FEN1ALOX5APJAK2 | |
| SCHEMBL27033266 | 0.94 | JAK2 (0.33) | P2RX3P2RX2FEN1ALOX5APJAK2 | |
| SCHEMBL27033324 | 0.83 | INPPL1 (0.34) | P2RX3P2RX2JAK2JAK1TYK2 | |
| SCHEMBL25520074 | 0.79 | RPS6KA3 (0.36) | P2RX3P2RX2FEN1ALOX5APJAK2 | |
| SCHEMBL25522341 | 0.78 | RPS6KA3 (0.36) | P2RX3P2RX2FEN1ALOX5APJAK2 | |
| SCHEMBL31538918 | 0.77 | JAK2 (0.33) | P2RX3P2RX2JAK2JAK1TYK2 | |
| SCHEMBL27033288 | 0.77 | JAK2 (0.33) | P2RX3P2RX2JAK2JAK1TYK2 | |
| SCHEMBL25522055 | 0.71 | VRK1 (0.35) | P2RX3P2RX2FEN1ALOX5APJAK2 | |
| SCHEMBL27033369 | 0.70 | SYK (0.37) | AURKB | |
| SCHEMBL27033260 | 0.69 | CA12 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558478-A1 | ARYL HYDROCARBON RECEPTOR AGONIST PRODRUGS AND METHODS OF USE THEREOF | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) | 2025-05-28 | — | — | EP | claimed |
| CN-119894865-A | Aryl hydrocarbon receptor agonist prodrugs and methods of use thereof | 元启(苏州)生物制药有限公司 | 2025-04-25 | — | — | CN | claimed |
| WO-2024020170-A1 | ARYL HYDROCARBON RECEPTOR AGONIST PRODRUGS AND METHODS OF USE THEREOF | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-01-25 | — | — | WO | claimed |
| EP-4558478-A1 | ARYL HYDROCARBON RECEPTOR AGONIST PRODRUGS AND METHODS OF USE THEREOF | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) | 2025-05-28 | — | — | EP | disclosed |
| CN-119894865-A | Aryl hydrocarbon receptor agonist prodrugs and methods of use thereof | 元启(苏州)生物制药有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2024020170-A1 | ARYL HYDROCARBON RECEPTOR AGONIST PRODRUGS AND METHODS OF USE THEREOF | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020170-A1 | ARYL HYDROCARBON RECEPTOR AGONIST PRODRUGS AND METHODS OF USE THEREOF | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-01-25 | — | — | WO | disclosed |